Antibody construct

• US 5,837,821 A
• Filed: 06/24/1994
• Issued: 11/17/1998
• Est. Priority Date: 11/04/1992
• Status: Expired due to Term

• Current Assignee: City of Hope
• Original Assignee: City of Hope
• Inventors: Wu, Anna M.
• Primary Examiner(s): Eisenschenk, Frank C.
• Application Number:
  US08/256,156
• Time in Patent Office: 1,607 Days
• Field of Search: 530/387.3, 530/387.7, 530/866, 530/867, 435/69.7, 435/240.1, 435/320.1, 435/252.3, 435/252.33
• US Class Current: 530/387.3
• CPC Class Codes: C07K 16/00 Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies antibodies with enzymatic activity, e.g. abzymes C12N9/0002
• CPC Class Codes: C07K 16/3007 Carcino-embryonic Antigens
• CPC Class Codes: C07K 16/468 Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
• CPC Class Codes: Y10S 530/866 involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain
• CPC Class Codes: Y10S 530/867 involving immunoglobulin or antibody produced via recombinant dna technology

Abstract

An antigen binding protein construct or "minibody" which includes the VL and VH domains of a native antibody fused to the hinge region and CH3 domain of the immunoglobulin molecule is described. Minibodies are small versions of whole antibodies which encode in a single chain the essential elements of a whole antibody. Minibodies are expressed by host cells transformed with minibody genes.

Claims

1. A minibody dimer as depicted by FIG. 2.

19. The minibody dimer of claim 1, consisting essentially of the light and heavy chain variable domains of the T84.66 CEA antibody fused to hinge and CH3 domains of human IgG.

2. A minibody consisting essentially of the light and heavy chain variable domains of a native antibody fused to hinge and CH3 domains of an immunoglobulin molecule as depicted by FIG. 1.

3. The minibody consisting essentially of the light and heavy chain variable domains of the T84.66 CEA antibody fused to the hinge and CH3 domains of human IgG.

4. The T84.66 minibody depicted by FIG. 3C.

5. E. coli RV308 transformed with a plasmid having an expression vector containing the nucleic acid sequence of a minibody gene as defined by claim 4.

6. A method for constructing a minibody as depicted by FIG. 1, which comprises:

(i) providing a single chain antibody including the variable light chain and variable heavy chain domains of a native antibody, and

(ii) fusing said single chain antibody to a construct of a native antibody hinge region and CH3 domain.

7. A method as defined by claim 6 in which said native antibody is a CEA antibody.

8. A method as defined by claim 6 in which said native antibody is T84.66 CEA antibody.

9. A method as defined by claim 6 in which said antibody is T84.66 antibody to CEA and in which said hinge region and CH3 domain are the human IgG hinge region CH3 domain.

10. The single chain T84.66 CEA antibody depicted by FIG. 3A (SEQ ID NO:

1).

11. A method of producing a minibody depicted by FIG. 1 or FIG. 2 which comprises transforming a host cell with an expression vector containing the nucleic acid sequence of a minibody gene and culturing the transformed host cell under conditions which permit expression of said nucleic acid sequence by said host cell.

14. A minibody produced by the method of claim 11 or claim 12.

12. A method of producing a T84.66 minibody as depicted by FIG. 3C which comprises transforming a host cell with an expression vector containing the nucleic acid sequence of said minibody and culturing the transformed host cell under conditions which permit expression of said nucleic acid sequence by the host cell.

13. A method as defined by claim 12 in which said host cell is E. coli.

15. A minibody consisting essentially of the light and heavy chain variable domains of an antibody fused to, in sequence, the hinge region of an antibody, an amino acid linker and the CH₃ domain of an immunoglobulin molecule.

16. A minibody in accordance with claim 15, wherein said amino acid linker comprises glycine and serine residues.

17. A minibody consisting essentially of

(a) a first single chain construct consisting essentially of a light chain variable region joined to a heavy chain variable region which is fused, in sequence, to hinge and CH₃ domains of an immunoglobulin molecule, and

(b) a second single chain construct consisting essentially of a light chain variable region joined to a heavy chain variable region which is fused to, in sequence, a hinge and CH₃ domains of an immunoglobulin molecule,

wherein said first single chain construct is linked to said second single chain construct by disulfide bonds between the hinge regions.

18. A minibody consisting essentially of

(a) a first single chain construct consisting essentially of a light chain variable region joined to a heavy chain variable region which is fused, in sequence, to a hinge region, an amino acid linker and a CH₃ domain of an immunoglobulin molecule, and

(b) a second single chain construct consisting essentially of a light chain variable region joined to a heavy chain variable region which is fused, in sequence, to a hinge region, an amino acid linker and a CH₃ domain of an immunoglobulin molecule,

wherein said first single chain construct is linked to said second single chain construct by disulfide bonds between the hinge regions.